We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Brian G Condie is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 2001 — 2005 |
Condie, Brian G |
R01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Regulation of Gabaergic Neuron Differentiation @ Medical College of Georgia (McG)
DESCRIPTION (provided by applicant): Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian central nervous system. Although GABAergic neurons are essential for proper nervous system development and function, very little is known about their formation and differentiation. The long-term goal of the proposed experiments is to gain an understanding of the mechanisms regulating GABAergic differentiation. The proposed work will dissect the coordinate regulation of the genes required for the GABAergic phenotype. These studies are focused on the embryonic expression and regulation of the mammalian glutamate decarboxylase genes, Gad1 and Gad2, and the gene encoding the vesicular GABA transporter (VGAT, also known as the vesicular inhibitory amino acid transporter or VIAAT). The Gad genes encode the GABA biosynthetic enzymes while the VGAT/VIAAT gene encodes the transporter that packages GABA into synaptic vesicles. Their coordinate activation and regulation is necessary for normal GABAergic differentiation and function. The proposed experiments are organized into three Specific Aims. In the first Specific Aim, the expression patterns of Gad1, Gad2 and VGAT/VIAAT are being defined by in situ hybridization analysis in mouse embryos. This is revealing the co-expression of these genes during early neural differentiation. In the second Aim, a novel cell culture system developed in the investigators laboratory is used to test the activity of specific transcription factors in activating the Gad and VGAT/VIAAT genes in neural progenitor cells. This culture system is based on differentiation of mouse embryonic stem cells containing tagged "knockin" alleles of the Gad1, Gad2 or VGAT/VIAAT genes. The factors being tested are expressed in the developing mesencephalon, diencephalon and telencephalon and are involved in GABAergic development. The stem cell experiments measure the activity of these proteins on the endogenous Gad and VGAT/VIAAT control sequences. In the third Aim, genetic crosses between a Gad1-lacZ "knockin" mouse strain developed by the PI and transcription factor knockout mice are used to test the role of these proteins in Gad1 regulation in vivo. The same transcriptional regulators examined in Aim 2 are being tested in the genetic crosses of Aim 3. This combined in vitro and in vivo approach allows the activity of a particular factor in the cell system to be linked with its function in the intact embryo. The proposed experiments will lead to new insights into the co-ordinate regulation of GABAergic neuron differentiation during fetal development.
|
1 |
| 2008 — 2009 |
Condie, Brian G |
R21Activity Code Description:
To encourage the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) |
A New Site Specific Recombinase For Mammalian Genome Engineering @ University of Georgia (Uga)
[unreadable] DESCRIPTION (provided by investigator): Site specific recombinases (SSRs) play a critical role in mammalian genetic analysis. The central goal of the work proposed in this application is to develop a new SSR, for genome engineering in stem cells and mice. At the present time, two SSRs, Cre and Flpe, are widely used and have been incorporated into the gene targeting and gene trapping designs of the International Knockout Mouse Consortium. Additional SSRs with target site specificities differing from Flpe and Cre will enable new strategies that are a significant advancement beyond current approaches. The central goal is to test the capabilities of the Dre recombinase as an additional SSR for use in ES cells and mice. Based on previously published work and new preliminary studies in my lab, we know that although Dre is related to the Cre recombinase, it does not react with the Cre target site loxP in bacteria or in mammalian cells. The work proposed in this application will carefully test the efficiency and specificity of the Dre recombinase in stem cells and in the developing central nervous system of mice. The proposed studies will provide essential new information required for the use of a new recombinase research tool by the research community. We will also generate valuable research resources including a mouse strain that expresses Dre in neural precursors as well as a Dre activity reporter mouse strain and embryonic stem cells. PUBLIC HEALTH RELEVANCE The proposed experiments will generate a new site-specific recombinase tool for use in genome engineering applications. This genetic tool will be useful to the research community for generating animal models of human genetic diseases and disorders. [unreadable] [unreadable]
|
1 |
